Development and validation of the AURIS score for predicting candidaemia in Candidozyma auris-colonised patients in the intensive care unit: a bicentric retrospective cohort study
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Puchades, F.
- Alonso-Ecenarro, F.
- Guna, R.
- Ferrer Gómez, C.
- Ortega-García, M.P.
- Abril López de Medrano, V.
Grupos
Abstract
Background: Candidozyma auris is an emerging multidrug-resistant pathogen that frequently colonises hospitalised patients and can cause invasive disease. Traditional tools, such as the Candida score, perform poorly in this setting. We aimed to externally validate and refine a clinical prediction model for C auris candidaemia among colonised patients in the intensive care unit (ICU). Methods: We performed a retrospective analysis of prospectively and systematically collected cohort data from ICUs in two tertiary-care hospitals in Valencia, Spain, to predict candidaemia among adult C auris-colonised patients during prolonged outbreaks (October, 2017, to March, 2020). A previously derived logistic regression-based prediction model was externally validated, then refined in a bicentric cohort using Elastic Net regression. Internal validation was performed by bootstrap resampling (n=5000). Model discrimination and calibration were assessed and compared with the Candida score. Findings: In the external validation cohort, 216 C auris-colonised ICU patients were included, of whom 31 (14%) developed candidaemia. After pooling this cohort with the original derivation cohort, a bicentric dataset of 422 patients was obtained, with 68 (16%) candidaemia events. Four predictors were retained: total parenteral nutrition (TPN; p<0·0001), previous antifungal therapy (p=0·027), multifocal colonisation (p=0·0020), and urinary isolation (p=0·029). These formed a simplified four-variable model (AURIS score) with a validated area under the curve of 0·81, outperforming the Candida score (0·75; p=0·0003). A graphical nomogram and point-based score for bedside risk estimation was created. At a 28% threshold, sensitivity was 0·72, specificity 0·84, and negative predictive value 0·94. Interpretation: The AURIS score provides a pragmatic tool for risk stratification among C auris-colonised ICU patients, with value in identifying those at low risk of candidaemia, reducing unnecessary empirical antifungal therapy. Its predictors highlight the risk in multi-colonised carriers, the relevance of urinary colonisation, the ecological advantage from previous antifungal exposure, and the strong association with TPN. Broader validation across diverse clades and epidemiological settings is warranted before widespread implementation. Funding: None. Translation: For the Spanish translation of the abstract see Supplementary Materials section. © 2026 Elsevier Ltd
Copyright © 2026 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Datos de la publicación
- ISSN/ISSNe:
- 1473-3099, 1474-4457
- Tipo:
- Article
- Páginas:
- 671-679
- PubMed:
- 41720147
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 10,236 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
LANCET INFECTIOUS DISEASES ELSEVIER SCI LTD
Documentos
- No hay documentos
Filiaciones
Proyectos y Estudios Clínicos
Contratos Juan Rodés 2021. Alba Ruiz.
Investigador Principal: ALBA CECILIA RUIZ GAITÁN
JR21/00061 . INSTITUTO DE SALUD CARLOS III . 2022
Contratos Miguel Servet 2025. GARCIA BUSTOS, VICTOR
Investigador Principal: VÍCTOR GARCÍA BUSTOS
CP25/00054 . INSTITUTO DE SALUD CARLOS III . 2026
Cita
GARCIA V,Puchades F,Alonso F,CABAÑERO MD,RUIZ A,PEMÁN J,SALAVERT M,TASIAS M,CALABUIG E,Guna R,Ferrer C,Ortega MP,Abril López de Medrano V. Development and validation of the AURIS score for predicting candidaemia in Candidozyma auris-colonised patients in the intensive care unit: a bicentric retrospective cohort study. Lancet Infect. Dis. 2026. 26. (7):p. 671-679. IF:29,400. (1).
Portal de investigación